Quantum Biopharma (QNTM) Competitors $17.15 -2.01 (-10.49%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$17.45 +0.30 (+1.75%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock QNTM vs. LIMN, CADL, PVLA, DBVT, SGMT, IMMP, ACB, NGNE, TVRD, and BTMDShould you be buying Quantum Biopharma stock or one of its competitors? The main competitors of Quantum Biopharma include Liminatus Pharma (LIMN), Candel Therapeutics (CADL), Palvella Therapeutics (PVLA), DBV Technologies (DBVT), Sagimet Biosciences (SGMT), Prima BioMed (IMMP), Aurora Cannabis (ACB), Neurogene (NGNE), Tvardi Therapeutics (TVRD), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Quantum Biopharma vs. Its Competitors Liminatus Pharma Candel Therapeutics Palvella Therapeutics DBV Technologies Sagimet Biosciences Prima BioMed Aurora Cannabis Neurogene Tvardi Therapeutics biote Quantum Biopharma (NASDAQ:QNTM) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability. Does the media refer more to QNTM or LIMN? In the previous week, Quantum Biopharma and Quantum Biopharma both had 1 articles in the media. Quantum Biopharma's average media sentiment score of 0.41 beat Liminatus Pharma's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liminatus Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is QNTM or LIMN more profitable? Liminatus Pharma's return on equity of 0.00% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Quantum BiopharmaN/A -155.20% -94.90% Liminatus Pharma N/A N/A N/A Which has higher valuation and earnings, QNTM or LIMN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuantum BiopharmaN/AN/A-$14.20M-$15.98-1.07Liminatus PharmaN/AN/AN/AN/AN/A Do institutionals and insiders hold more shares of QNTM or LIMN? 1.2% of Quantum Biopharma shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryQuantum Biopharma beats Liminatus Pharma on 3 of the 5 factors compared between the two stocks. Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNTM vs. The Competition Export to ExcelMetricQuantum BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.60M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E RatioN/A8.2819.9620.26Price / SalesN/A283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book3.787.538.035.65Net Income-$14.20M-$55.14M$3.18B$249.15M7 Day Performance-21.04%4.61%2.93%3.28%1 Month Performance11.00%0.90%1.72%3.95%1 Year PerformanceN/A5.40%34.39%20.98% Quantum Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNTMQuantum BiopharmaN/A$17.15-10.5%N/AN/A$49.60MN/A0.00N/ALIMNLiminatus PharmaN/A$11.15+17.6%N/AN/A$246.62MN/A0.00N/AGap UpCADLCandel Therapeutics2.4754 of 5 stars$5.06+3.3%$22.00+334.8%-12.4%$245.50M$120K-3.7860Analyst RevisionGap UpPVLAPalvella Therapeutics3.4434 of 5 stars$22.54+2.1%$46.29+105.3%N/A$244.11M$42.81M-1.86N/ADBVTDBV Technologies3.7508 of 5 stars$9.16+3.2%$14.75+61.0%+175.1%$243.22M$4.15M-1.8680Analyst UpgradeGap UpSGMTSagimet Biosciences2.4124 of 5 stars$7.62-3.2%$26.60+249.1%+175.2%$241.41M$2M-4.338IMMPPrima BioMed0.9709 of 5 stars$1.64flat$7.00+326.8%-11.9%$239.50M$5.14M0.002,021Positive NewsACBAurora Cannabis0.1956 of 5 stars$4.24+2.2%N/A-5.1%$233.29M$246.72M38.551,130NGNENeurogene3.8085 of 5 stars$14.95-7.5%$46.17+208.8%-41.3%$230.48M$930K-3.4490News CoveragePositive NewsTVRDTvardi TherapeuticsN/A$23.33-5.2%$71.50+206.5%N/A$230.37M$7.14M0.0080BTMDbiote3.0897 of 5 stars$4.02-4.3%$8.00+99.0%-43.0%$229.78M$197.19M6.59194News CoveragePositive News Related Companies and Tools Related Companies Liminatus Pharma Alternatives Candel Therapeutics Alternatives Palvella Therapeutics Alternatives DBV Technologies Alternatives Sagimet Biosciences Alternatives Prima BioMed Alternatives Aurora Cannabis Alternatives Neurogene Alternatives Tvardi Therapeutics Alternatives biote Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNTM) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
